Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis

Brewer, George J.; Dick, Robert; Ullenbruch, Matthew; Jin, Hong; Phan, Sem H.

doi:10.1016/j.jinorgbio.2004.10.006

Cited by 48 publications

(43 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4). This is consistent with previous reports in other models (Askari et al, 2004;Brewer et al, 2004). Because TM seems to have both anti-inflammatory and antifibrotic effects, it was important to study TM in a system such as the BDL model, which induces rapid hepatic fibrosis with only a modest inflammatory response.…”

Section: Discussionsupporting

confidence: 90%

Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis

Song¹,

Song²,

Barve³

et al. 2008

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis

Song¹,

Song²,

Barve³

et al. 2008

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

“…ATM has been shown to decrease the secretion of several cytokines, that are crucial for the progression and survival of cancer cells, including VEGF-A,B, bFGF, IL-6 TNF-a [6][7][8]. Additionally, NF K B signaling is one of the important pathways in maintaining the proliferation and survival of cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…Successful tumors, like other hypoxic tissues, attempt to establish a blood supply by secreting one or more vascular endothelial growth factors (VEGFs) which promote the in-growth and expansion of microvessel networks to the tumor. The vascular endothelial growth factors and cytokines that play a major role in the process of tumor viability and neo-vascularization include VEGF-A,B, IL-6, FGF-b and TNF-a [6][7][8]. These factors have been targeted in several research studies attempting to limit cancer growth and angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Tetrathiomolybdate early (Brewer, Dick, Ullenbruch, Jin, & Phan, 2004) 16 CXCL11 early (Burdick et al, 2005) …”

Section: Idmentioning

confidence: 99%

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Moeller

Ask

Warburton

et al. 2008

The International Journal of Biochemistry & Cell Biology

841

724

View full text Add to dashboard Cite

Different animal models of pulmonary fibrosis have been developed to investigate potential therapies for idiopathic pulmonary fibrosis (IPF). The most common is the bleomycin model in rodents (mouse, rat and hamster). Over the years, numerous agents have been shown to inhibit fibrosis in this model. However, to date none of these compounds are used in the clinical management of IPF and none has shown a comparable antifibrotic effect in humans. We performed a systematic review of publications on drug efficacy studies in the bleomycin model to evaluate the value of this model regarding transferability to clinical use. Between 1980 and 2006 we identified 246 experimental studies describing beneficial antifibrotic compounds in the bleomycin model. In 221 of the studies we found enough details about the timing of drug application to allow inter-study comparison. 211 of those used a preventive regimen (drug given ≤ day 7 after last bleomycin application), only 10 were therapeutic trials (> 7 days after last bleomycin application). It is critical to distinguish between drugs interfering with the inflammatory and early fibrogenic response from those preventing progression of fibrosis, the latter likely much more meaningful for clinical application. All potential antifibrotic compounds should be evaluated in the phase of established fibrosis rather than in the early period of bleomycin-induced inflammation for assessment of its antifibrotic properties. Further care should be taken in extrapolation of drugs successfully tested in the bleomycin model due to partial reversibility of bleomycin induced fibrosis over time. The use of alternative and more robust animal models, which better reflect human IPF, is warranted.

show abstract

Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis

Cited by 48 publications

References 47 publications

Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis

Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis

Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Contact Info

Product

Resources

About